ClinicalTrials.gg
Not yet recruitingNCT07739329Updated Jul 31, 2026

A Study on the Preventive Effect of Electroacupuncture Combined With Dexmedetomidine in Post-stroke Depression

A Phase 4 interventional study of Dexmedetomidine and Electropuncture in Post-stroke Depression, sponsored by Min Su. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Min Su · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
231
Allocation
Randomized
Sex
All
01

Study summary

Post-stroke depression (PSD) is a common neuropsychiatric complication following stroke and has emerged as a major public health concern due to its adverse impact on post-stroke prognosis. Clinical studies have confirmed that early intervention with electroacupuncture can significantly reduce PSD incidence and alleviate depressive severity. Mechanistically, electroacupuncture exerts antidepressant effects through inhibition of the endoplasmic reticulum stress pathway and attenuation of neuronal apoptosis. Dexmedetomidine, a highly selective α₂-adrenergic receptor agonist, not only provides sedation and analgesia but also confers neuroprotective actions, including anti-inflammatory, anti-apoptotic, and blood-brain barrier protective effects. Its efficacy in preventing postpartum depression has been clinically validated. Given the substantial burden of PSD and the limitations of existing preventive approaches, the present study aims to investigate the value of a combined electroacupuncture and dexmedetomidine strategy for PSD prevention, with the goal of developing a safe and effective integrative treatment regimen for this frequent post-stroke complication.

02

Conditions studied

  • Post-stroke Depression
03

In context

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 231 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Min Su is the lead sponsor of 13 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ischemic stroke with a disease course of less than 2 weeks;
  • Patients with high-risk PSD;
  • The patient can accept the treatment plan described in this trial and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment;
  • Severe aphasia or significant language impairment;
  • Disturbance of consciousness;
  • History of psychiatric disorders, including but not limited to depression, schizophrenia, and bipolar disorder;
  • Alcohol or substance dependence;
  • Use of sedatives or antipsychotic medications within 2 weeks prior to screening;
  • Severe cardiac, hepatic, or renal dysfunction;
  • Complicated with acute severe conditions or unstable vital signs;
  • Pregnancy or lactation;
  • or intolerance to electroacupuncture;
  • Sick sinus syndrome, severe bradycardia (heart rate \< 50 bpm), second-degree or higher atrioventricular block, permanent pacemaker implantation, severe heart failure, or \< 30%;
  • Known allergy to any of the study medications;
  • Inability to complete the study procedures due to any unavoidable circumstances.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
231 participants (estimated)

Study arms

  • Placebo comparator
    Control group

    The control group was given an equal dose of normal saline and sham electroacupuncture treatment.

    Drug: Normal Saline (NS) · Drug: Shame electropuncture

  • Active comparator
    Electroacupuncture group

    The electroacupuncture group was given an equal dose of normal saline and received electroacupuncture treatment.

    Drug: Electropuncture · Drug: Normal Saline (NS)

  • Active comparator
    The electroacupuncture combined with dexmedetomidine group

    The electroacupuncture combined with dexmedetomidine group was given intranasal titration of dexmedetomidine (original form, 1 μg/kg), and was treated with electroacupuncture simultaneously.

    Drug: Dexmedetomidine · Drug: Electropuncture

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence of PSD 3 months after stroke

    Time frame: 3 months after stroke

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 4 months is below that.

Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07739329
Lead sponsor
Min Su
Responsible party
Min Su (Professor of Anesthesiology, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Jul 31, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 31, 2026

Study contacts

Yanping Zhang
Contact
zhangyp8415@163.com
+8615223049366

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion